Antipsychotic-like effects of TAAR1 agonists and D2 receptor blockers are mediated through distinct modulation of striatal neuronal dynamics
- 21 July 2026
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (11) , 6559-6571
Abstract
Trace amine-associated receptor 1 (TAAR1) agonists are being investigated as potential new treatments for schizophrenia, a disorder characterized by striatal hyperdopaminergia and dysregulated cortical and hippocampal glutamatergic function. Current evidence suggests that TAAR1 agonists reduce elevated striatal dopamine synthesis capacity and release, likely through direct inhibition of presynaptic dopaminergic neurons and modulation of upstream glutamatergic signaling. However, their impact on postsynaptic striatal neuronal dynamics and associated behaviors remains largely unexplored. Here we investigated the effects of TAAR1 agonists, RO5166017 and clinical drug candidate ulotaront, on in vivo calcium dynamics of D1- and D2-receptor expressing medium spiny neurons (MSNs) in freely behaving mice, under normal and phencyclidine (PCP)-induced, psychosis-like conditions. Both ulotaront and RO5166017 mitigated PCP-induced alterations in locomotor behavior, MSN activity levels and spatiotemporal dynamics. Interestingly, the neural effects were dependent on both locomotor activity and the psychosis-like state. While ulotaront and RO5166017 differentially affected neuronal activity levels under normal conditions, they both produced a similar increase in the PCP state, specifically during movement, with comparable effects observed in D1 and D2 MSNs. Although the established antipsychotics haloperidol and clozapine produced similar behavioral effects, their impact on striatal MSNs was distinct and lacked prominent state dependence. These findings provide new insights into the distinct neurocircuit changes associated with the antipsychotic-like effects of TAAR1 agonists, distinguishing them from D2 receptor-targeting treatments.Keywords
This publication has 70 references indexed in Scilit:
- Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophreniaEuropean Archives of Psychiatry and Clinical Neuroscience, 2023
- In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of SchizophreniaPharmaceutical Research, 2022
- TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase InhibitionBiological Psychiatry, 2021
- Schizophrenia—An OverviewJAMA Psychiatry, 2020
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatmentWorld Psychiatry, 2020
- Trace Amine-Associated Receptor 1 Modulation of Dopamine System2016
- Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychoticsPsychopharmacology, 2010
- Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in micePsychopharmacology, 1997
- Corticostriatal innervation of the patch and matrix in the rat neostriatumJournal of Comparative Neurology, 1996
- Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissueEuropean Journal of Pharmacology, 1992